Quick Facts

• High Blood Pressure: Helps achieve a reduction in high blood pressure (hypertension).
• BPH Symptoms: Used to manage the signs and symptoms associated with Benign Prostatic Hyperplasia (BPH).

---

Кардура (Doxazosin) is a prescribed medication utilized to support the management of two primary health conditions. It is an established option that can be used alone or combined with other therapeutic agents as part of a comprehensive treatment strategy.

Therapeutic Applications

1. Management of Hypertension: This medication is approved for the treatment of high blood pressure. By acting on the vascular system, it assists in lowering overall blood pressure, which serves to reduce the risk of associated cardiovascular events, such as stroke and myocardial infarction.

2. Addressing BPH Symptoms: It is also indicated for managing the urinary symptoms related to benign prostatic hyperplasia (BPH) in men. The medication helps to relieve related lower urinary tract symptoms, such as the sensation of incomplete bladder emptying, urinary frequency, and a weak stream. It works to support urinary flow by encouraging the relaxation of muscles in the prostate and bladder neck area.

Regulatory References

1. NIH DailyMed guidance for Doxazosin

Eligibility Map: Who Can and Cannot Use Doxazosin

Official regulatory documents define the population eligibility for Doxazosin (Кардура) primarily for adults to treat Benign Prostatic Hyperplasia (BPH) symptoms and Hypertension (Immediate-Release formulation only).

---

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Patients with a known hypersensitivity to doxazosin, other quinazolines, or any excipients. Patients with a history of orthostatic hypotension or hypotension (for BPH indication).
Conditions for non-use (BPH)	As monotherapy in patients with overflow bladder, anuria, or progressive renal insufficiency.
Age-related eligibility rules	Children and adolescents are not recommended due to lack of established safety and efficacy data. Geriatric patients (aged ge 70 years) may be at higher risk for hypotension with the Extended-Release (XL) formulation.
Condition-specific limitations	Severe hepatic impairment patients are not recommended for use (XL formulation). Mild or moderate hepatic impairment requires particular caution. Prostate cancer must be ruled out before starting BPH treatment.
Pregnancy and lactation eligibility	Pregnancy: No adequate safety data; use is only if benefit outweighs risk. Lactation: Use is generally contraindicated or not recommended.

---

This structure establishes absolute exclusions based on allergies and hemodynamic risk, and mandates conditional use requiring specific patient monitoring or pre-treatment checks. The profile restricts use in populations where safety or efficacy data are lacking, such as those with severe hepatic impairment or in the pediatric age group.

Interactions with other medicines and products

Doxazosin's official regulatory profile identifies potential interactions structured around pharmacodynamic potentiation and pharmacokinetic modification.

---

Pharmacodynamic Interactions

Co-administration with agents that lower blood pressure can result in additive hypotensive effects. This includes other antihypertensive agents and other alpha-blockers. Concomitant use with Phosphodiesterase-5 (PDE-5) Inhibitors (such as Sildenafil) carries an official caution for the risk of symptomatic hypotension (low blood pressure with symptoms). To address this risk, regulatory documents recommend a 6-hour time interval between the administration of Doxazosin and a PDE-5 Inhibitor.

---

Pharmacokinetic Interactions

Doxazosin is classified as a CYP 3A4 substrate. Caution is required when co-administering Doxazosin with strong CYP 3A4 inhibitors (e.g., Ketoconazole) due to the potential for increased systemic exposure. The administration of Cimetidine has been documented to result in a 10% increase in the mean Area Under the Curve (AUC). Co-administration with food results in a reduction in concentration; however, this effect is officially not clinically significant for the Immediate-Release formulation.

---

Population-Specific Constraints

Use of Doxazosin is not recommended in patients with severe hepatic impairment due to a lack of established clinical data. Caution is also formally advised for all patients with impaired hepatic function as the drug is metabolized by the liver.

Selective Blockade of alpha1-Adrenergic Receptors

Doxazosin operates primarily as a selective competitive antagonist at the post-synaptic alpha1-Adrenergic Receptor (alpha1-AR) located on smooth muscle tissue. By occupying the receptor site, the drug prevents the binding of the sympathetic neurotransmitter, norepinephrine, thereby interrupting the G q-protein signaling cascade. This inhibition prevents the increase of intracellular calcium concentration, resulting in a direct decrease in the contractile state of smooth muscle across both vascular and urogenital systems.

---

Dual Modulation of Urogenital and Vascular Tone

Blockade of alpha1 B subtypes on arterial and venous smooth muscle leads to systemic vasodilation and a reduction in Total Peripheral Resistance (TPR). Concurrently, blockade of the alpha1 A subtype in the prostate and bladder neck causes the rapid reduction of muscle tension, which reduces dynamic compression on the urethra. Furthermore, Doxazosin engages a complementary, alpha1-independent pathway to induce apoptosis (programmed cell death) in prostatic stromal cells, which affects the structural bulk of the tissue over time.

The administration of Кардура (Doxazosin) is based on a once-daily oral protocol, with specific instructions governing dosage, timing, and preparation based on the tablet form.

Dosing and Administration

Feature	Description
Route of Administration	Oral.
Dosing Schedule	Initial dose is 1 mg once daily (Immediate-Release, IR) or 4 mg once daily (Extended-Release, XL). The maximum daily dose for hypertension is 16 mg (IR); the maximum for BPH is 8 mg (IR/XL).
Frequency & Timing	Taken once daily. Dose increases (titration) occur at 1 to 2 week intervals for the IR tablet and 3 to 4 week intervals for the XL tablet.
Timing Relative to Meals	IR tablets may be taken without regard to food. XL tablets must be administered with breakfast.
Preparation Constraints	XL tablets must be swallowed whole. They must not be crushed, cut, divided, or chewed.

Procedural and Population Rules

• Formulation Restriction: The XL formulation is restricted to the Benign Prostatic Hyperplasia (BPH) indication; it is not approved for the treatment of hypertension.
• Reinitiation: If therapy is discontinued for several days, the entire treatment must be restarted at the lowest initial dose (1 mg or 4 mg) and re-titrated.
• Renal and Hepatic Function: No dosage adjustment is explicitly required for renal impairment. Caution is advised when administering the drug to patients with hepatic impairment, and use is not recommended in cases of severe impairment.

Connection to the Overall Use Protocol

These instructions establish a standardized, low-start, slow-titration protocol that defines how the drug is administered over time. These rules mandate adherence to formulation-specific conditions, such as the required co-administration of the XL tablet with breakfast and the physical prohibition against altering the tablet structure. This structured framework dictates the operational use of the drug.

Research Evidence Overview for Кардура (Doxazosin)

---

Evidence for use in Benign Prostatic Hyperplasia (BPH)

Research has explored the evaluation of Кардура in studies involving men with BPH, a condition marked by functional limitations related to the lower urinary tract. Studies for this condition primarily consisted of short-term and intermediate-term Randomized Controlled Trials (RCTs). The research monitored outcomes related to physical discomfort and changes in urinary function, such as flow rates and symptom severity scores, which are patient-reported outcomes describing perceived discomfort.

The research provides context on how changes in symptoms were reported during the defined study intervals. However, long-term effects are not fully established. Follow-up durations were limited in many key studies, meaning there is limited information for long-term outcomes regarding the sustained effects on urinary function.

Evidence for use in High Blood Pressure (Hypertension)

Research explored the evaluation of Кардура in studies involving individuals experiencing high blood pressure. The research for this indication often involved larger clinical trials and retrospective analyses that explored how blood pressure measurements changed. The studies monitored outcomes related to systemic or functional imbalance, such as shifts in systolic and diastolic blood pressure readings, and observed patient responses over defined time intervals.

These studies report how symptoms evolved in the observed populations, indicating that blood pressure measurements may change during the study period. The collected data show patterns related to the specific blood pressure measures used in the study.

A key limitation is that comparative evidence is lacking for certain situations, and the follow-up durations were limited for fully understanding patterns related to cardiovascular health over very extended periods. Data are still emerging for how these effects relate to long-term functional stability across all individuals with high blood pressure.

What is Still Uncertain About the Research

The available research provides context but not individual predictions about how any person will respond. The evidence highlights what is known—and what is still uncertain. Evidence quality varies across studies, and the interpretation of outcomes is complicated by the fact that sample sizes were modest in some key trials. Furthermore, the long-term effects are not fully established for either BPH or high blood pressure.

Common questions about Кардура (FAQ)

Q: What is the main difference between Кардура and other similar medicines for blood pressure?

A: Official documents classify this medicine as a selective alpha-1 adrenergic antagonist, often called an alpha-blocker. It works by blocking specific receptors on smooth muscle to help reduce the resistance of blood flow in the vessels, which is its method for lowering blood pressure. This targeted mechanism is generally distinct from how other major drug classes treat hypertension.

Q: How quickly does Кардура start to work after I take the first dose?

A: The full therapeutic benefit on symptoms, such as those related to BPH or blood pressure, is typically observed gradually. In clinical studies, this benefit was often fully assessed after one to two weeks of treatment. However, some initial effects, like a drop in blood pressure upon standing, are often noted within a few hours following the first dose.

Q: What happens if I stop taking Кардура suddenly?

A: Official guidance states that if treatment is stopped for several days, the entire therapy must be restarted at the lowest dose and built up slowly again. While studies have reported a return to previous blood pressure levels without severe withdrawal symptoms, a careful approach to stopping the drug is necessary. Any decision regarding stopping or changing the dose should be made in consultation with a healthcare provider.

Q: What is the longest time a person can safely be on Кардура?

A: This medicine is generally prescribed for the long-term management of high blood pressure and BPH symptoms. Clinical trials, particularly for BPH, have documented maintained effects over treatment periods lasting up to two years. Regulatory sources indicate that data for very long-term safety across all populations is limited, which emphasizes the need for regular clinical follow-up.

Q: Are there any specific foods or supplements that interact with Кардура?

A: The active substance is processed in the liver by the CYP3A4 enzyme, which means substances like grapefruit juice may increase the amount of the drug in your system. Since many herbal remedies and nutritional supplements are not formally tested for drug interactions, consultation with a healthcare provider is necessary before combining any supplements or herbal remedies with this medication.

Q: Can women take Кардура?

A: The immediate-release formulation of the medicine is officially indicated for the management of high blood pressure, a condition that applies to adults regardless of sex. However, the extended-release formulation is only approved for treating Benign Prostatic Hyperplasia (BPH), a condition specific to men.

Q: Why did my doctor prescribe Кардура instead of a different drug for my condition?

A: Official information notes that this drug is often a choice due to its potential dual-action, addressing two conditions through one mechanism. It is an alpha-blocker that can treat high blood pressure while also relieving BPH symptoms by relaxing smooth muscle in both the vascular system and the prostate.

Q: Can Кардура affect my ability to drive or operate machinery?

A: Official documentation confirms that this medicine may cause common side effects such as drowsiness, dizziness, or a decrease in overall alertness. This risk is highest when first starting treatment or when the dosage is increased. Official guidance advises patients to assess their reaction to the medicine before driving or operating machinery.

Q: Is there a time of day when it is best to take Кардура?

A: Official administration guidelines specify the timing based on the formulation used. The immediate-release tablets can generally be taken once a day in the morning or evening, with or without food. In contrast, the extended-release tablets must be administered once daily alongside breakfast.

Q: What are the differences in side effects between the immediate-release and extended-release forms of Кардура?

A: The general safety profiles for both the immediate-release and extended-release formulations are broadly similar. However, the official FDA label notes a specific warning that geriatric patients (age 70 and older) may have a higher risk of experiencing low blood pressure with the Extended-Release (XL) formulation.

Q: Can the drug be split or crushed, or must it be taken whole?

A: The extended-release tablets must be swallowed whole and are strictly forbidden from being chewed, cut, crushed, or divided. Immediate-release tablets, if they have a functional score mark, may be split to assist in precise dosing during titration. Any alteration to the tablet structure must be discussed with a healthcare provider.

Q: Does alcohol interact with Кардура?

A: Official sources caution that alcohol consumption may need to be avoided or limited while taking this medicine. Alcohol is known to increase the potential risk of low blood pressure (hypotension) and may lead to associated symptoms such as fainting or severe dizziness.

Q: Is there a generic version of Кардура available?

A: Yes, according to official FDA product databases, both the immediate-release tablet and the extended-release tablet formulations have approved generic equivalents. The actual availability of these generic versions may vary based on your location and pharmacy stock.

Q: What are the ingredients in Кардура besides the main drug substance?

A: The drug contains the active substance Doxazosin, along with several inactive ingredients, also known as excipients, which are necessary for the tablet structure. Official product descriptions list common excipients, which can include microcrystalline cellulose, lactose, and magnesium stearate. The specific coloring agents often vary based on the strength of the tablet.

Q: Does Кардура interact with commonly used over-the-counter pain relievers?

A: Regulatory guidance suggests that over-the-counter pain relievers should be taken only after consulting a healthcare provider. Certain common pain medications, especially those belonging to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, may potentially interfere with the medicine's blood pressure-lowering effects.

Q: What should be done if a dose of Кардура is forgotten?

A: Official guidelines suggest taking the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular schedule should be continued. Taking a double dose to compensate for a missed dose is not recommended.

Q: Does Кардура affect cholesterol levels?

A: Clinical data summarized in official sources suggests that the medicine may be associated with beneficial changes in serum lipids, including total cholesterol and triglycerides, in some patient populations. This is an observation from studies that included individuals being treated for blood pressure management.

Q: Can taking Кардура cause swelling in the ankles or feet?

A: Swelling in the ankles or feet, known as peripheral edema, is not listed as one of the most frequently reported side effects. However, some official safety lists, including post-marketing reports, do include descriptions of swelling in the lower legs as an uncommon event associated with the medication.

Q: Does Кардура have a black box warning in regulatory documents?

A: The official FDA label and regulatory documents for this medication do not currently include a Boxed Warning. This type of warning, sometimes called a Black Box Warning, is reserved for drugs that carry a significant risk of serious or life-threatening adverse effects.

Q: How is Кардура eliminated from the body?

A: Official pharmacological information indicates that the active substance is extensively processed in the liver, primarily through an enzyme pathway known as CYP3A4. Following this metabolism, approximately 63% of the drug is eliminated from the body via the feces, with a smaller portion excreted in the urine.

Q: Is there any research on the use of Кардура in patients with diabetes?

A: Yes, studies that explored the long-term management of high blood pressure often included patients who had concurrent conditions, such as non-insulin-dependent diabetes mellitus (NIDDM). Furthermore, some research data suggests that this medication may be associated with a beneficial effect on glucose (blood sugar) metabolism.

Q: What kind of monitoring (blood tests, etc.) is usually needed while taking Кардура?

A: Blood pressure checks are required to monitor the effectiveness of the drug if it is being taken for high blood pressure. For BPH treatment, regulatory guidance requires that the presence of prostate cancer be clinically ruled out before starting therapy.

How to Store and Dispose of Cardura (Doxazosin)

Official regulatory guidelines define specific conditions for storing and disposing of Cardura tablets to ensure product quality and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature (e.g., 15 C to 30 C).
Protection	Keep the medication protected from excess heat and moisture (humidity).
Packaging	Keep the tablets in the tightly closed container they came in.
Safety	The product must be stored out of the reach of children.

Disposal Instructions

Disposal of unused or expired Cardura should follow official guidance. Do not flush the medicine down the toilet or pour it into a drain unless specifically instructed. Dispose of the product through a local medicine take-back program or follow authorized instructions for discarding the medicine safely with household trash. Environmental release of the waste product should be avoided.